Latham & Watkins Advises on CureVac’s Upsized Public Offering of Common Shares

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has announced the pricing of 27,027,028 common shares in an underwritten public offering at a public offering price of US$9.25 per share for gross proceeds of approximately US$250 million. CureVac has granted the underwriters a 30-day option to purchase up to an additional 4,054,054 common shares to be sold in the offering on the same terms and conditions. All of the shares in the offering are to be sold by CureVac N.V. The offering is expected to close on or about February 10, 2023, subject to customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Adam Johnson and MacLane Taggart.